Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study
1999 (English)In: Human Reproduction, ISSN 0268-1161, E-ISSN 1460-2350, Vol. 14, no 3, 838-841 p.Article in journal (Refereed) Published
The aim of this study was to evaluate the therapeutic efficacy of intravenous immunoglobulin (IVIG) in the prevention of recurrent spontaneous abortion (RSA). In a double-blind, randomized, placebo-controlled study, 41 women with a history of unexplained recurrent spontaneous abortion were treated with IVIG or saline infusions during pregnancy. The birth of a child was considered a successful outcome. The overall success rate was 77% in the IVIG group compared with 79% in the placebo group. For women with primary RSA the success rates were 82 (IVIG) and 89% (placebo), and for women with secondary RSA the rates were 73 (IVIG) and 70% (placebo). We found no statistically significant difference in treatment results between IVIG and placebo.
Place, publisher, year, edition, pages
1999. Vol. 14, no 3, 838-841 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-25896DOI: 10.1093/humrep/14.3.838Local ID: 10337OAI: oai:DiVA.org:liu-25896DiVA: diva2:246444